Tuesday, October 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 12, 2026

SK Hynix Joins the Nasdaq. But This Nasdaq-100 Semiconductor Stock Could Be an Even Better Buy for the Second Half of 2026.

View original at nasdaq.com
SK Hynix Joins the Nasdaq. But This Nasdaq-100 Semiconductor Stock Could Be an Even Better Buy for the Second Half of 2026. Key Points The memory chip shortage is one of the biggest bottlenecks for artificial intelligence (AI)…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ASML has a virtual monopoly on extreme ultraviolet (EUV) machines.

    60% confidence
  • SK Hynix will never join the S&P 500 because it is a South Korean company, similar to Taiwan Semiconductor Manufacturing.

    60% confidence
  • Demand for SK Hynix memory chips is far outpacing supply, creating a multi-year runway for future growth that has propelled the company to a $1 trillion valuation.

    60% confidence
  • ASML is an even better Nasdaq-100 stock than SK Hynix for investors seeking a fundamental AI stock to buy and hold for at least five years.

    60% confidence
  • ASML is the better buy for folks with a long-term investing time horizon compared to memory stocks like SK Hynix.

    60% confidence
  • ASML doesn't design or manufacture chips; it produces advanced machines needed to perform the lithography step in semiconductor manufacturing.

    60% confidence
  • Stock Advisor's total average return is 929%, a market-crushing outperformance compared to 211% for the S&P 500.

    60% confidence
  • In Q1 2026, memory's share of ASML net system sales rose to 51% (from 42% in Q1 2025), while logic's share fell to 49% (from 58% in Q1 2025).

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com